
Sign up to save your podcasts
Or


Guest: Mitchell R. Humphreys, M.D. (@MayoMitch)
Host: Darryl S. Chutka, M.D. (@ChutkaMD)
Prostate cancer is a very common malignancy in men, second only to skin cancer. Despite the fact that it’s one of the more treatable malignancies, it remains the 2nd leading cause of cancer death in men. When diagnosed early, it has an excellent prognosis. The 5-year survival rate approaches 100% in those with local or regional disease. Although screening for prostate cancer is available, the use of screening tests has been controversial and recommendations regarding its use, confusing. Listen in to get a urologist’s perspective.
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
By Mayo Clinic4.4
276276 ratings
Guest: Mitchell R. Humphreys, M.D. (@MayoMitch)
Host: Darryl S. Chutka, M.D. (@ChutkaMD)
Prostate cancer is a very common malignancy in men, second only to skin cancer. Despite the fact that it’s one of the more treatable malignancies, it remains the 2nd leading cause of cancer death in men. When diagnosed early, it has an excellent prognosis. The 5-year survival rate approaches 100% in those with local or regional disease. Although screening for prostate cancer is available, the use of screening tests has been controversial and recommendations regarding its use, confusing. Listen in to get a urologist’s perspective.
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

319 Listeners

550 Listeners

698 Listeners

503 Listeners

259 Listeners

894 Listeners

3,376 Listeners

278 Listeners

1,148 Listeners

516 Listeners

368 Listeners

12 Listeners

18 Listeners

15 Listeners

9 Listeners

261 Listeners

424 Listeners

45 Listeners

15 Listeners

323 Listeners

271 Listeners